Results 111 to 120 of about 85,817,771 (286)

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

open access: yesArthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss   +9 more
wiley   +1 more source

IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention

open access: yesImmunoTargets and Therapy
Tim Schumertl, Juliane Lokau, Christoph Garbers Institute of Clinical Biochemistry, Hannover Medical School, Hannover, 30625, GermanyCorrespondence: Christoph Garbers, Institute of Clinical Biochemistry, Hannover Medical School, Carl-Neuberg-Strasse 1 ...
Schumertl T, Lokau J, Garbers C
doaj  

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

open access: yesArthritis Care &Research, EarlyView.
Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures.
Kevin Byram   +25 more
wiley   +1 more source

Interleukin-6 [PDF]

open access: yesGeneral Internal Medicine and Clinical Innovations, 2018
A. M. Gressner, O. A. Gressner
openaire   +2 more sources

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho   +4 more
wiley   +1 more source

The diagnostic utility of procalcitonin, interleukin-6 and interleukin-8, and hyaluronic acid in the Norwegian consensus definition for early-onset neonatal sepsis (EONS)

open access: yes, 2018
Britt Nakstad1,2 1Department of Paediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway; 2Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway Introduction: A key challenge in ...
Britt Nakstad, Nakstad B
core   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

Elevated Liver Enzymes Is Not an Impediment to Allopurinol Dose Escalation: An Observational Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective Routine liver enzyme monitoring is advocated for while on allopurinol, but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzyme levels in patients with gout commenced on allopurinol. Methods One hundred and fifty patients with gout and normal baseline serum aminotransferases initiated on ...
May Shuen Tang   +4 more
wiley   +1 more source

Revisiting the 1986 molecular cloning of interleukin 6

open access: yesFrontiers in Immunology, 2014
Toshio eHirano
doaj   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy